Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
172.57
Oct 22 • 3:59 PM ET Dollar change+4.12 Percentage change(2.45%)
Aftermarket Close
172.50
Aftermarket • 7:49 PM ET Dollar change-0.07 Percentage change(-0.04%)
Today, 10:40 AMAstraZeneca launches lung cancer drug Zegfrovy (sunvozertinib) in U.S. for EGFR exon 20-mutated NSCLC after FDA accelerated approval
Index
-
Market Cap
267.64B
Enterprise Value
294.98B
Income
10.45B
Sales
61.37B
Book/sh
32.43
Cash/sh
3.20
Employees
96100
IPO
Oct 17, 2003
P/E
25.79
Forward P/E
15.10
PEG
1.30
P/S
4.36
P/B
5.32
P/C
53.87
P/FCF
24.62
EV/EBITDA
14.68
EV/Sales
4.81
Quick Ratio
0.67
Current Ratio
0.89
Debt/Eq
0.64
LT Debt/Eq
0.52
Option/Short
Yes / Yes
EPS (ttm)
6.69
EPS next Y
11.43
EPS next Q
2.59
EPS this Y
11.93%
EPS next Y
11.49%
EPS next 5Y
11.59%
EPS past 3/5Y
45.90% 22.05%
Sales past 3/5Y
9.82% 16.31%
EPS Y/Y TTM
25.90%
Sales Y/Y TTM
8.61%
EPS Q/Q
2.26%
Sales Q/Q
6.41%
Insider Own
3.44%
Insider Trans
-0.02%
Inst Own
60.67%
Inst Trans
-1.05%
ROA
9.15%
ROE
21.99%
ROIC
13.69%
Gross Margin
73.93%
Oper. Margin
22.38%
Profit Margin
17.02%
SMA20
6.25%
SMA50
6.00%
SMA200
-4.39%
Trades
Shs Outstand
1.55B
Shs Float
1.50B
52W High
212.71 -18.87%
52W Low
153.41 12.49%
Volatility
1.67% 1.90%
ATR (14)
3.77
RSI (14)
64.77
Beta
0.33
Rel Volume
0.82
Avg Volume
3.38M
Volume
2,773,282
Perf Week
3.53%
Perf Month
5.66%
Perf Quarter
1.96%
Perf Half Y
-10.26%
Perf YTD
-1.67%
Perf Year
2.55%
Perf 3Y
34.97%
Perf 5Y
39.42%
Perf 10Y
189.06%
Prev Close
168.45
Price
172.57
Change %
2.45%
Date Action Analyst Rating Change Price Target Change
Sep-15-26Upgrade Deutsche Bank Sell → Hold
Sep-09-26Initiated RBC Capital Mkts Outperform
Jul-13-26Downgrade HSBC Securities Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.
CFO & Executive DirectorDr. Aradhana Sarin M.D.
EVP of Global opt. & ITMs. Pam P. Cheng
Head of Investor RelationsMr. Joris Silon
CHROMr. Jeffrey Pott J.D.